Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss of $0.06/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sensus Healthcare Reports Record Second Quarter Financial Results
August 3, 2017 4:01 PM EDTBOCA RATON, Fla., Aug. 3, 2017 /PRNewswire/ --Â Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results for the three and six months ended June 30, 2017.
Highlights of the second quarter of 2017 and recent weeks include (all comparisons are with the second quarter of 2016, unless otherwise noted):
Reported record revenues of $5.0 million, up 39% compared with $3.6 million Achieved gross margin of 68.7%, up from 65.0% Increased sales organization headcount to 27 including... More